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Background: In this study, we investigated the effect of Samchulkunbi-tang water extract (SCTE) in an established
mouse model of ovalbumin (OVA)-induced allergic asthma. The effects of SCTE on the production of Th1 and Th2
cytokines, eotaxin, and total and OVA-specific immunoglobulin E, inducible nitric oxide synthase expression, and
matrix metalloproteinase-9 activity were measured.
Methods: Mice were sensitized on days 0 and 14 with an intraperitoneal injection of 20 μg ovalbumin (OVA)
emulsified in 2 mg aluminum hydroxide in 200 μL PBS buffer. On days 21, 22, and 23, mice received an airway
exposure to OVA (1%, w/v, in PBS) for 1 h. SCTE was administered orally to mice at doses of 200 and 400 mg/kg
per day from days 18 to 23.
Results: SCTE reduced the number of inflammatory cells, cytokines, and chemokines in bronchoalveolar lavage
fluids and iNOS expression and MMP-9 activity in mouse lung tissue. Histological studies using hematoxylin & eosin
and periodic acid-schiff staining showed that SCTE substantially inhibited OVA-induced inflammatory cell infiltration
in lung tissue and goblet cell hyperplasia in the airway. SCTE also reduced IL-4 and IL-13 expression in
concanavalin-A-stimulated splenocytes. These results were similar to those obtained with montelukast as a
positive control.
Conclusions: Collectively, these results suggest that SCTE may be an effective oral treatment for allergic airway
inflammation by virtue of its anti-inflammatory activity.
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Asthma, one of the most prevalent diseases worldwide,
is a chronic respiratory disease characterized by heigh-
tened airway inflammation, airway hyperresponsiveness,
and airflow obstruction in response to specific triggers.
The chronic inflammation is associated with airway
hyperresponsiveness that leads to recurrent episodes of
wheezing, breathlessness, chest tightness, and coughing,
particularly at night or in the early morning. These epi-
sodes are usually associated with widespread but variable
airflow obstruction that is often reversible either* Correspondence: hkshin@kiom.re.kr
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reproduction in any medium, provided the orspontaneously or with treatment [1]. Eosinophilic in-
flammation, which has long been considered as import-
ant pathogenesis hallmark of asthma, features in many
contemporary definitions of asthmatic disease [2]. The
mechanism responsible for asthma involves infiltration
of eosinophils into the lung, where they preferentially
stimulate T-helper 2 (Th2) cell responses by presenting
antigens [3]. Therefore, Th2 cells are important primar-
ily in the airways [4], and Th2 cytokines such as inter-
leukin (IL)-4, IL-5, and IL-13 play pivotal roles in the
pathophysiology of asthma [5]. IL-33 has recently
emerged as a potential therapeutic target in the treat-
ment of asthma [6]. Excessive release of IL-33 from asth-
matic bronchial epithelial cells may occur in response to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7] because the chronically inflamed asthmatic epithe-
lium is more susceptible to injury than is normal
epithelium.
NO level increases in the airways in animal models of
asthma and in patients with asthma [8]. Measurement of
exhaled NO has been suggested as helpful for monitor-
ing airway inflammation in asthma, especially in cases of
exacerbated asthma [9]. Another important aspect of
asthma is that the matrix metalloproteinase-9 (MMP-9)
level increases significantly in the bronchoalveolar lavage
fluid (BALF), blood, and sputum of people with asthma
[10]. MMP-9 belongs to a family of extracellular pro-
teases that are responsible for the degradation of the
extracellular matrix during tissue remodeling [11].
Therefore, the control of nitric oxide synthase (NOS)
and MMP-9 activities is an important aspect of asthma
treatment.
Samchulkunbi-tang (shen zhu jian pi tang in Chinese)
is a herbal formula that is used widely in Korean trad-
itional medicine in the treatment of chronic gastritis,
gastric ulcers, and gastroptosis. Several researchers have
reported that Samchulkunbi-tang has pharmacological
activities in processes such as immune regulation [12]
and gastroprotection [13]. Ginseng radix, one of the
constituents of Samchulkunbi-tang, has been used to
prevent various diseases including diabetes, cancer, al-
lergy, and hypertension [14] and to treat inflammation
[15]. Atractylodis rhizoma alba, another constituent of
Samchulkunbi-tang, has been reported to inhibit mel-
anin biosynthesis [16]. However, to our knowledge, there
are no reports on the antiasthmatic activity of Sam-
chulkunbi-tang. Patients with chronic asthma who take
antiasthmatic drugs (including corticosteroids) for a long
and indefinite time may develop serious side effects [17].
The present study was designed to determine if SCTE
has anti-inflammatory and antiasthmatic effects in a
mouse model of OVA-induced airway inflammation.
Methods
Preparation of SCTE
Samchulkunbi-tang was prepared according to a transi-
tional herbal formula listed in Table 1. The chopped
herbs were combined in the listed ratios and extracted
in distilled water at 100°C for 2 h. The yield of lyophi-
lized extract from starting crude materials was about
24.5%. The dried extract was dissolved in PBS.
Experimental protocol
Seven-week-old female BALB/c pathogen-free mice were
purchased from Orient Co. Ltd (Seoul, Korea) and main-
tained in an animal facility under standard laboratory
conditions for one week before the experiments. Ani-
mals were provided water and standard chow adlibitum. All experimental procedures were carried out in
accordance with the NIH Guidelines for the Care and
Use of Laboratory Animals and were approved by Korea
Institute of Oriental Medicine Institutional Animal Care
and Use Committee. The animals were cared for in ac-
cordance with the dictates of the National Animal Wel-
fare Law of Korea. The modified protocols for mice
sensitization and challenge were used as described previ-
ously [18].
Administration of SCTE
SCTE (200 mg/kg or 400 mg/kg) was administered or-
ally once daily on days 28–30. Negative control (NC)
and positive control mice were treated orally with PBS
and montelukast (30 mg/kg, Sigma, St Louis, MO,
USA), respectively, once daily on days 28–30. Animals
were sacrificed 48 h after the last challenge (i.e., on day
32) to characterize the effects of SCTE. A schematic dia-
gram of the treatment schedule is shown in Figure 1.
Measurement of total cell, eosinophil, lymphocyte,
neutrophil, and macrophage cell counts in BALF
Differential cell counting was performed as described
previously [18].
Measurement of cytokine and chemokine levels in BALF
Levels of IL-4, IL-13, IL-33, tumor necrosis factor-α
(TNF-α), and eotaxin in BALF were measured using
enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer’s instructions (BioSource
International, Camarillo, CA, USA) as described
Figure 1 Mouse model of airway inflammation and effects of SCTE.
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5 are 0 to 1000 pg/mL and 0 to 500 pg/mL, respectively.Measurement of total and OVA-specific immunoglobulin
E (IgE) levels in plasma
Serum was collected via centrifugation (200 × g, 10 min)
and stored at −70°C. Total and OVA-specific IgE levels
were measured using ELISAs as described previously [18].Histopathology
For histological examination, before the lungs were
removed, the left lungs were filled intratracheally with a
fixative (0.8% formalin, 4% acetic acid) using a ligature
around the trachea. The tissues were embedded in paraf-
fin, sectioned at 4 μm thickness, and stained with
hematoxylin and eosin (H&E) (both from Sigma) and
periodic acid-Schiff (PAS) solution (IMEB Inc., San Mar-
cos, CA, USA) to assess mucus production. Tissues were
mounted and coverslips were attached using mounting
medium (Invitrogen, CA, USA). The degree of cell infil-
tration in the airway was scored in a double-blind screen
by two independent investigators. The peri-bronchiole
and peri-vascular inflammation was evaluated using a
score of 0–5 as described previously [19]. For each
mouse, five airway sections that were randomly distribu-
ted through the left lung were analyzed, and their aver-
age scores were calculated. Quantitative analysis of
mucus production was performed using an image
analyzer (Leica Microsystem Imaging Solutions Ltd.,
Cambridge, UK).Measurement of MMP-9 level in lung tissue
Zymography in lung tissue was performed as described
previously [19] with some modifications. Lung tissues
were homogenized (1/10 w/v) in tissue lysis/extraction
reagent plus protease inhibitor (Sigma-Aldrich) to ob-
tain extracts of lung tissues. After centrifugation
(12,000 g, 4°C, 10 min), the protein concentration in
the supernatants was determined using a protein assay
reagent (Bio-Rad Laboratories) according to the manu-
facturer’s instructions, and equal amounts of total pro-
tein were loaded for gelatin zymography (60 μg/lane).Western blotting
Equal amounts of total lung protein (30 μg) were heated
at 100°C for 5 min, loaded onto 8% SDS-PAGE gels, and
separated by electrophoresis, after which the bands were
transferred to a nitrocellulose membrane (at 100 V for
2 h). The membranes were blocked for 1 h with Tris-
buffered saline containing 0.05% Tween 20 (TBST) plus
5% skim milk and were incubated with anti-inducible
NOS (iNOS, 1:1000 dilution), anti-NF-κB p65, anti-β-
actin (1:1000 dilution), and anti-MMP-9 (1:1000 dilution)
overnight at 4°C. The membranes were washed three
times with TBST and then incubated with a 1:10,000 dilu-
tion of horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. The membranes
were washed three times with TBST and then developed
using an enhanced chemiluminescence kit.
Preparation and treatment of splenocyte suspensions
Spleens from BALB/c mice were removed aseptically,
and single-cell suspensions were generated by passing
the cells twice through a needle in RPMI 1640 medium
containing 10% (v/v) FBS, 25 mM HEPES, 2 mM glu-
tamine, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (GibcoBRL, NY, USA). The red blood cells
were lysed in lysis buffer (Sigma) at 37°C for 10 min.
The separated splenocytes were washed with PBS
and cultured in 100 mm dishes for 4 h. The splenocytes
were plated into 96-well plates at a density of 1 × 106
cells/mL and treated with different concentrations of p-
hydroxycinnamic acid methyl ester for 1 h, followed
by treatment with concanavalin A (ConA; 1 μg/mL) for
a further three days. The IL-4 and IL-13 levels in the
culture supernatants were measured with ELISA kits
for murine cytokines (BioSource International) accord-
ing to the manufacturer’s instructions.
Statistical analysis
The data are expressed as mean ± standard deviation. Stat-
istical comparisons were performed using one-way analysis
of variance, with significance set at P < 0.05 or P < 0.01.
Results
Effects of SCTE on cell numbers in BALF
Infiltration of eosinophils in the airway causes abnormal
production of inflammatory proteins and cytokines, such
Figure 2 Effects of SCTE on the recruitment of inflammatory cells to bronchoalveolar lavage fluid (BALF) of mice 48 h after the final
ovalbumin (OVA) challenge. Cells were isolated by centrifugation and stained with Diff-QuikW Stain reagent. Cell numbers were determined by
counting within at least five squares of a hemocytometer using a light microscope. Dead cells, stained with Trypan blue, were excluded from the
total cell count. PBS/PBS, PBS-sensitized/challenged, negative control (NC, PBS only administration); OVA/PBS, OVA-sensitized/challenged mice
(PBS only administration); OVA/mon, OVA-sensitized/challenged mice (montelukast 30 mg/kg); OVA/SCTE-200, OVA-sensitized/challenged mice
(SCTE 200 mg/kg); OVA/SCTE-400, OVA-sensitized/challenged mice (SCTE 400 mg/kg). SCTE or montelukast was given 1 h before the challenge.
Significantly different from PBS/PBS, ##P < 0.01; significantly different from OVA, *P < 0.05, **P < 0.01.
Figure 3 Effects of SCTE on cytokine and chemokine levels in BALF. BALF was collected from mice 48 h after the last OVA challenge. Individual
samples were analyzed using ELISA. (A) IL-4; (B) IL-13; (C) IL-33, (D) TNF-α, (E) eotaxin. PBS/PBS, PBS-sensitized/challenged, negative control (PBS only);
OVA/PBS, OVA-sensitized/challenged mice (PBS only); OVA/mon, OVA-sensitized/challenged mice (montelukast 30 mg/kg); OVA/SCTE-200, OVA-
sensitized/challenged mice (SCTE 200 mg/kg); OVA/SCTE-400, OVA-sensitized/challenged mice (SCTE 400 mg/kg). SCTE or montelukast was given 1 h
before the challenge. Significantly different from PBS/PBS, ##P < 0.01; significantly different from OVA, *P < 0.05, **P < 0.01.
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Figure 4 Effects of SCTE on the levels of total and OVA-specific IgE in plasma. Plasma was collected from mice 48 h after the final OVA
challenge. Each sample was analyzed using ELISA. (A) Total IgE level, (B) OVA-specific IgE level. PBS/PBS, PBS-sensitized/challenged, negative
control (PBS only); OVA/PBS, OVA-sensitized/challenged mice, (PBS only); OVA/mon, OVA-sensitized/challenged mice (montelukast 30 mg/kg);
OVA/SCTE-200, OVA-sensitized/challenged mice (SCTE 200 mg/kg); OVA/SCTE-400, OVA-sensitized/challenged mice (SCTE 400 mg/kg). SCTE or
montelukast was given 1 h before the challenge. Significantly different from PBS/PBS, ##P < 0.01; significantly different from OVA, *P < 0.05,
**P < 0.01.
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of SCTE on various cell types present in BALF. As
shown Figure 2, the numbers of total cells, macrophages,
and eosinophils in BALF decreased significantly in a
dose-dependent manner after SCTE treatment. The
positive control also showed a significant decrease in
total cell number in BALF after SCTE treatment
(Figure 2).
Effects of SCTE on Th2-type cytokine and chemokine
levels in BALF
Because SCTE reduced the number of inflammatory
cells in BALF, we investigated the effects of SCTE on
Th2-type cytokines by measuring the levels of IL-4, IL-
13, IL-33, and TNF-α. As shown in Figure 3A–D, the
levels of these cytokines increased in the OVA-sensi-
tized/challenged group and decreased in the SCTE-
treated group compared with the NC group. Because
eotaxin level is associated with eosinophilia in BALF, we
measured the eotaxin levels in BALF. Similar to thelevels of Th2-type cytokines, eotaxin level increased in
the OVA-sensitized/challenged group and decreased in a
dose-dependent manner in the SCTE-treated group
(Figure 3E).
Effects of SCTE on total and OVA-specific IgE levels
Systemic changes observed in the mouse model were
examined further by measuring the serum concentra-
tions of total and OVA-specific IgE levels in plasma. The
OVA-specific IgE concentration increased in asthmatic
mice but was undetectable in nonasthmatic control
mice. By contrast, the total and OVA-specific IgE con-
centrations were lower in the SCTE-treated mice com-
pared with the OVA-induced asthmatic mice (Figure 4A
and B).
Effects of SCTE on airway inflammatory cell recruitment
and mucus production in lung tissue
Lung inflammation is a characteristic hallmark of the al-
lergic response to an allergen. In view of the finding that
Figure 5 (See legend on next page.)
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Figure 5 Effects of SCTE on the recruitment of leukocytes (A), mucus production (B), scoring of the extent of inflammation via
quantitative analysis of inflammatory cell infiltration (C), scoring of mucus production (D) in lung tissue. Histological examination of lung
tissues was performed 48 h after the final OVA challenge. Lung tissues were fixed, sectioned at 4 μm thickness, and stained with H&E (A) solution
or PAS (B). PBS/PBS, PBS-sensitized/challenged, negative control (PBS only); OVA/PBS, OVA-sensitized/challenged mice, (PBS only); OVA/mon,
OVA-sensitized/challenged mice (montelukast 30 mg/kg); OVA/SCTE-200, OVA-sensitized/challenged mice (SCTE 200 mg/kg); OVA/SCTE-400,
OVA-sensitized/challenged mice (SCTE 400 mg/kg). SCTE or montelukast was given 1 h before the challenge. Significantly different from PBS/PBS,
##P < 0.01; significantly different from OVA, *P < 0.05, **P < 0.01.
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BALF, we examined its antiasthmatic effects via micro-
scopic examination of lung tissue. The extent and the
anatomical location of the leukocyte infiltrates were
determined by examining H&E-stained tissue obtained
from mice 48 h after the final allergen challenge. Tissue
from the OVA-sensitized/challenged group showed
widespread peribronchiolar and perivascular inflamma-
tion, comprising primarily eosinophils. Tissue from the
mice given SCTE had substantially fewer eosinophils
and macrophages in the peribronchial regions and air-
spaces compared with the NC group (Figure 5 A and C).
Although respiratory mucus protects the lower airways
from dehydration and damage, excessive secretion by
hyperplastic goblet cells contributes to the morbidity
and mortality of many respiratory diseases, including
asthma. To determine whether SCTE suppressed mucus
overproduction induced by goblet cell hyperplasia, lung
sections were stained with PAS. In OVA-sensitized/chal-
lenged mice, mucus overproduction was observed clearly
as a violet color in the bronchial airways compared withFigure 6 Effect of SCTE on iNOS expression in lung tissue. iNOS protei
PBS-sensitized/challenged, negative control (PBS only); OVA/PBS, OVA-sensi
challenged mice (montelukast 30 mg/kg); OVA/SCTE-200, OVA-sensitized/ch
challenged mice (SCTE 400 mg/kg). SCTE or montelukast was given 1 h bethat observed in the PBS/PBS group. The extent of
mucus staining was markedly diminished in a dose-
dependent manner in OVA-induced mice treated with
SCTE (Figure 5 B and D).
Effects of SCTE on iNOS and NF-κB p65 levels in
lung tissue
During OVA-induced allergic airway inflammation, the
concentration of iNOS and NF-κB p65 in nuclear pro-
tein extracts from lung tissues was increased signifi-
cantly in OVA-sensitized/challenged mice compared
with the NC group. By contrast, the iNOS (Figure 6A
and B) and NF-κB p65 (Figure. 7A and B).level was sig-
nificantly lower in the SCTE-treated group compare to
OVA-induced group
Effects of SCTE on MMP-9 activity in lung tissue
Zymography showed that MMP-9 activity increased
in OVA-induced mice but decreased in SCTE-
treated OVA-induced mice compared with NC mice.
The reduction in MMP-9 activity was consistentn levels were measured 48 h after the last challenge; PBS/PBS,
tized/challenged mice, (PBS only); OVA/mon, OVA-sensitized/
allenged mice (SCTE 200 mg/kg); OVA/SCTE-400, OVA-sensitized/
fore the challenge.
Figure 7 Effect of SCTE on NF-κB activity in lung tissue. NF-κB p65 protein level was measured 48 h after the last challenge; PBS/PBS,
PBS-sensitized/challenged, negative control (PBS only); OVA/PBS, OVA-sensitized/challenged mice, (PBS only); OVA/mon, OVA-sensitized/
challenged mice (montelukast 30 mg/kg); OVA/SCTE-200, OVA-sensitized/challenged mice (SCTE 200 mg/kg); OVA/SCTE-400, OVA-sensitized/
challenged mice (SCTE 400 mg/kg). SCTE or montelukast was given 1 h before the challenge.
Figure 8 Effects of SCTE on MMP-9 activity and protein expression in lung tissues of mice. The protein was loaded for gelatin zymography
(60 μg/lane). SDS-PAGE zymography was performed according to previous method [19]. (A) MMP-9 activity and protein expression. (B)
Densitometry of MMP-9. PBS/PBS, PBS-sensitized/challenged, negative control (PBS only); OVA/PBS, OVA-sensitized/challenged mice (PBS only);
OVA/mon, OVA-sensitized/challenged mice (montelukast 30 mg/kg); OVA/SCTE-200, OVA-sensitized/challenged mice (SCTE 200 mg/kg);
OVA/SCTE-400, OVA-sensitized/challenged mice (SCTE 400 mg/kg). SCTE or montelukast was given 1 h before the challenge. Significantly different
from PBS/PBS, #P < 0.05, ##P < 0.01; significantly different from OVA, *P < 0.05, **P < 0.01.
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Figure 9 Effects of SCTE on IL-4 and IL-5 levels in splenocytes. (A) IL-4 level; (B) IL-5 level. Control, Con-A-stimulated cells, negative control
(PBS only); SCTE-50, Con-A stimulated + SCTE 50 μg/mL; SCTE-100, Con-A stimulated + SCTE 100 μg/mL; SCTE-200, Con-A stimulated + SCTE
200 μg/mL. Significantly different from control, *P < 0.05, **P < 0.01.
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MMP-9 expression increased in control OVA-induced
mice but decreased markedly in SCTE-treated mice
(Figure 8A and B).Effects of SCTE on Th2-type cytokine production
in splenocytes
We also examined the effects of SCTE on the produc-
tion of Th2-type cytokines (IL-4 and IL-13) by spleno-
cytes. Treatment with ConA (1 μg/mL) increased IL-4
and IL-13 production markedly in splenocytes. ConA-
stimulated IL-4 secretion by splenocytes was inhibited
by treatment with various concentrations of SCTE (50,
100, and 200 μg/mL) compared with the control. IL-13
level decreased only at an SCTE dose of 200 μg/mL
(Figure 9).Discussion
Our results show clearly that SCTE significantly modu-
lated the pulmonary environment of Th1- (TNF-α) and
Th2-type cytokines (IL-4, IL-13, and IL-33) and chemo-
kines (eotaxin) in BALF, and inhibited iNOS expression
and MMP-9 activity in the mouse lung tissue compared
with the effects in OVA-induced mice. SCTE decreased
the total and OVA-specific IgE level in plasma. In lung
histopathological studies using H&E and PAS staining,
SCTE inhibited inflammatory cell infiltration and mucus
hypersecretion compared with the effects in OVA-challenged mice. SCTE also reduced IL-4 and IL-13 ex-
pression in Con-A-stimulated splenocytes.
Th2-type cytokines such as IL-4, IL-5, and IL-13 play
important roles in the development of allergic asthmatic
responses in humans [20]. SCTE treatment reduced the
number of eosinophils in BALF and in the lung tissue
surrounding the airways, and decreased the extent of
goblet cell hyperplasia compared with untreated mice.
However, there was little change in the numbers of other
leukocytes such as neutrophils, lymphocytes, and macro-
phages. It is possible that the reduction in eosinophil
numbers observed in our study reflects a decrease in IL-
5-dependent eosinophil expansion. IL-5 plays an import-
ant role in the differentiation, maturation, and survival
of eosinophils, which lead to an increased number of
these cells in the airways subsequent to activation. A
previous study has shown that eosinophilic inflammation
does not develop in the absence of IL-5 or its signaling
in the airways of OVA-sensitized/challenged mice [21].
We found that SCTE reduced the production of IL-4,
IL-5, and IL-13. IL-4 promotes the differentiation and
proliferation of Th2-type T cells, and the switching of B
cells to produce IgG1 and IgE. Blocking of IL-4 by
monoclonal antibodies decreases IgE level and airway
eosinophilia in allergic mice [22]. Therefore, suppression
of IL-4 may also contribute to decreasing lung eosino-
philia. Increased immunoreactive IL-33 level has a var-
iety of effects on inflammatory cells. IL-33 is present in
the peripheral blood [23] and in BALF of asthmatic
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kine at high levels [24]. IL-33 drives production of
proinflammatory and Th2 cytokines by mast cells and
Th2 lymphocytes [25,26], induces chemotaxis of Th2
cells [27], promotes eosinophil and basophil adhesion,
and increases eosinophil survival and basophil migration
[28]. In the present study, IL-33 reduction by SCTE may
help decrease lung and BALF eosinophil numbers. Th2
cytokines, especially IL-13, are central mediators of
asthma, and IL-13 potently induces goblet cell metapla-
sia by human airway epithelial cells [29]. Therefore, in
the present study, the decrease of goblet hyperplasia
may reflect less IL-13 production compared with OVA-
induced mice.
TNF-α is also an important chemoattractant for the
recruitment of eosinophils into the lungs [30] and is a
potent modulator of the immune and inflammatory
responses. Inflammatory cells contribute to the gener-
ation of Th2 cytokines (IL-4, IL-5, and IL-13), chemo-
kines (eotaxin and RANTES), and TNF-α, whose levels
increase in the asthmatic lung [31]. In our experiments,
SCTE treatment reduced the levels of IL-4, IL-5, IL-13,
TNF-α, and eotaxin; these findings are consistent with
the change in inflammatory cell count in BALF. To iden-
tify the possible protective mechanism underlying the
activity of SCTE in airway inflammation, we used gelatin
zymography to evaluate the activity of MMP-9 and
Western blotting to evaluate the expression of MMP-9
protein in lung tissue. We were interested in the rela-
tionship between MMP-9 expression and infiltration of
inflammatory cells in lungs of the OVA-challenged mice.
SCTE-treated OVA-induced mice showed reduced activ-
ity and protein expression of MMP-9 in lung tissue
compared with control OVA-challenged mice. These
results are consistent with the observed changes in cyto-
kines. The dose-dependent changes are also consistent
with those shown in an in vivo experiment in rats [32].
Excessive NO may recruit eosinophils into the airway
and shift the balance toward Th2 cells, thus exacerbating
airway inflammation [33]. iNOS produces high amounts
of NO. The present results from our OVA-induced
asthma model showing decreased production of iNOS in
lung tissues, increased inflammatory cytokine levels, and
recruitment of eosinophils to the lung airways are con-
sistent with the study by Nathan. In our experiments,
SCTE significantly reduced goblet cell hyperplasia and
mucus production in the OVA-induced murine asth-
matic animals. Eosinophils infiltrating into the airway
also increase mucus secretion of epithelial goblet cells
[34]. These results suggest that mucus hypersecretion is
attenuated by the ability of SCTE to limit cytokine pro-
duction and eosinophilia, and that SCTE can inhibit the
development of the allergic status in the OVA-induced
asthma model.Conclusion
In summary, administration of SCTE in this mouse
asthma model significantly decreased the number of
eosinophils in BALF and lung tissue, and reduced IL-4
IL-5, IL-13, TNF-α, and eotaxin production in BALF and
total IgE and OVA-specific IgE levels in plasma after
OVA challenge. Administration of montelukast was
induced anti-inflammatory effects such as the reduction
in the numbers of eosinophils and macrophage into the
BALF, inflammatory cells infiltration in the lung tissue
and levels of cytokines and IgE in this study. These find-
ings suggest that SCTE may effectively inhibit the pro-
gression of airway inflammation of allergic asthma. The
anti-inflammatory effects of SCTE were mediated par-
tially by downregulation of MMP-9 and reduction in
iNOS expression.
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